A. Bossios (Stockholm, Sweden), M. McDonnell (Oranmore (Co Galway), Ireland)
Adult Bronchiectasis in the Northern Territory of Australia: The Aboriginal and Non-aboriginal comparative study
S. Mehra (Perth, Australia), L. Chor (Darwin, Australia), S. Campbell (Darwin, Australia), S. Heraganahally (Darwin, Australia)
|     |
Risk Factors Associated to Cardiovascular Events after Bronchiectasis Exacerbation: A Prospective Study.
L. Feced Olmos (Valencia, Spain), R. Méndez (Valencia, Spain), P. González-Jiménez (Valencia, Spain), L. Bouzas (Valencia, Spain), A. Piró (Valencia, Spain), V. Alcaraz-Serrano (Barcelona, Spain), R. Amaro (Barcelona, Spain), G. Scioscia (Barcelona, Spain), A. Torres (Barcelona, Spain), R. Menéndez (Valencia, Spain)
| |
Endotyping bronchiectasis through multi-omic profiling
H. Keir (Dundee, United Kingdom), A. Shoemark (Dundee, United Kingdom), M. Crichton (Dundee, United Kingdom), A. Dicker (Dundee, United Kingdom), J. Pollock (Dundee, United Kingdom), A. Giam (Dundee, United Kingdom), A. Cassidy (Dundee, United Kingdom), C. Fong (Dundee, United Kingdom), S. Finch (Dundee, United Kingdom), E. Furrie (Dundee, United Kingdom), G. Suarez-Cuartin (l'Hospitalet de Llobregat, Spain), T. Fardon (Dundee, United Kingdom), G. Einarsson (Belfast, United Kingdom), J. Elborn (Belfast, United Kingdom), S. Aliberti (Milan, Italy), O. Sibila (Barcelona, Spain), J. Huang (Dundee, United Kingdom), J. Chalmers (Dundee, United Kingdom)
| |
“Integrative microbiomics” reveals a disrupted interactome in bronchiectasis exacerbations
J. Narayana (Singapore, Singapore), M. Mac Aogáin (Singapore, Singapore), P. Tiew (Singapore, Singapore), N. Ali (Singapore, Singapore), A. Lim (Singapore, Singapore), H. Keir (Dundee, United Kingdom), A. Dicker (Dundee, United Kingdom), K. Thng (Singapore, Singapore), A. Tsang (Singapore, Singapore), T. Low (Singapore, Singapore), T. Ong (Singapore, Singapore), B. Oliver (Sydney, Australia), G. Yan Hui (Dundee, United Kingdom), A. Tee (Singapore, Singapore), M. Koh (Singapore, Singapore), J. Abisheganaden (Singapore, Singapore), K. Tsaneva-Atanasova (Exeter, United Kingdom), J. Chalmers (Exeter, United Kingdom), S. Chotirmall (Singapore, Singapore)
| |
A randomized controlled trial of 4 weeks of airway clearance with oscillating positive end expiratory pressure device versus autogenic drainage in people with bronchiectasis
M. Shteinberg (Haifa, Israel), N. Yaari (Haifa, Israel), N. Stein (Haifa, Israel), L. Bentur (Haifa, Israel), G. Livnat (Haifa, Israel), Y. Adir (Haifa, Israel)
| |
The Relationship Between Symptoms, Exacerbations And Treatment Response in Bronchiectasis
Y. Gao (zhengzhou, China), H. Abo-Leyah (Dundee, United Kingdom), S. Finch (Dundee, United Kingdom), M. Lonergan (Dundee, United Kingdom), S. Aliberti (Milan, Italy), A. De Soyza (Newcastle, United Kingdom), T. C Fardon (Newcastle, United Kingdom), G. Tino (Philadelphia, United States of America), J. D Chalmers (Dundee, United Kingdom)
| |
Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study
M. Loebinger (London, United Kingdom), E. Polverino (Barcelona, Spain), F. Blasi (Milan, Italy), S. Elborn (Belfast, United Kingdom), J. Chalmers (Scotland, United Kingdom), H. Tiddens (Rotterdam, Netherlands), H. Goossens (Antwerp, Belgium), M. Tunney (Belfast, United Kingdom), F. Ringshausen (Hannover, Germany), A. Hill (Edinburgh, United Kingdom), R. Pathan (Hyderabad, India), G. Angyalosi (Basel, Switzerland), C. Haworth (Cambridge, United Kingdom)
| |